STOCK TITAN

Atossa Therapeutics, Inc. - $ATOS STOCK NEWS

Welcome to our dedicated page for Atossa Therapeutics news (Ticker: $ATOS), a resource for investors and traders seeking the latest updates and insights on Atossa Therapeutics stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Atossa Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Atossa Therapeutics's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.08%
Tags
clinical trial covid-19
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.97%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.56%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.01%
Tags
clinical trial covid-19
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.29%
Tags
management
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.14%
Tags
covid-19
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
25.71%
Tags
covid-19
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.91%
Tags
earnings covid-19
Atossa Therapeutics, Inc.

Nasdaq:ATOS

ATOS Rankings

ATOS Stock Data

190.46M
117.48M
0.06%
12.98%
8.43%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States of America
SEATTLE

About ATOS

atossa therapeutics, inc. develops and markets medical devices, laboratory tests, and therapeutics to address breast health conditions in the united states. the company's lead program is the development of endoxifen, an active metabolite of tamoxifen which is in phase ii studies to treat and prevent breast cancer. it is also developing intraductal microcatheter technology to target the delivery of therapies, including fulvestrant, immunotherapies, and chimeric antigen receptor t-cell therapies, directly to the site of breast cancer. the company was formerly known as atossa genetics inc. and changed its name to atossa therapeutics, inc. in january 2020. atossa therapeutics, inc. was founded in 2009 and is headquartered in seattle, washington.